▼ Indacaterol for COPD
Copyright policy )▼ Indacaterol for COPD
▼Indacaterol powder for inhalation (Onbrez Breezhaler – Novartis) is a long-acting beta2 agonist, licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). In this article, we consider the evidence for indacaterol and how its use fits with current management strategies for COPD.
Dose-Response Relationship, Drug, Quinolones, Severity of Illness Index, United Kingdom, Bronchodilator Agents, Respiratory Function Tests, Pulmonary Disease, Chronic Obstructive, Cough, Forced Expiratory Volume, Administration, Inhalation, Indans, Practice Guidelines as Topic, Humans, Adrenergic beta-2 Receptor Agonists, Randomized Controlled Trials as Topic
Dose-Response Relationship, Drug, Quinolones, Severity of Illness Index, United Kingdom, Bronchodilator Agents, Respiratory Function Tests, Pulmonary Disease, Chronic Obstructive, Cough, Forced Expiratory Volume, Administration, Inhalation, Indans, Practice Guidelines as Topic, Humans, Adrenergic beta-2 Receptor Agonists, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).6 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!